Learning Objectives:

· Review Phase III clinical data (Trailblazer-Alz 2 study)

· Understanding trial setup/medication usage and adverse events (ARIA-E. ARIA-H)

· Reviewing clinically meaningful results and future implications/limitations

Session date: 
02/01/2024 - 7:30am CST
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Dr. Shayan Khazaei